Citi Pharma Limited secured regulatory clearance from the Competition Commission of Pakistan to purchase all shares of Pakheim International Pharma (Private) Limited, moving the planned buyout closer to finalization.
Citi Pharma announced in a material information notice sent to the Pakistan Stock Exchange on October 16, 2026, that the Competition Commission of Pakistan issued an order on October 9, 2026, clearing the transaction.
The commission approved the deal under Section 31(1)(d)(i) of the Competition Act, 2010, after evaluating the arrangement and finding no market competition issues, based on the corporate filing.
The purchase will move forward following the conditions of a share purchase agreement executed on May 6, 2026, pending the completion of necessary legal, regulatory, and additional procedures, according to Citi Pharma.
The firm stated that additional updates will be provided as required when the deal hits subsequent stages.
The transaction covers the complete share ownership of Pakheim International Pharma, though the financial value and expected monetary impact were not disclosed by Citi Pharma.
